⌘K
Loading ticker…
As of 2026-08-24, Forte Biosciences, Inc. Common Stock (FBRX) has a 3-month relative strength percentile of 99 and a leadership percentile of 99 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 99. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 0.2%, relative volume 0.46×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
FBRX is in a stage 2 uptrend, week 4. Currently in a 17-day base; basing ADR 0.2% (broad 9.4%). VCP detected: no. RS line below base-start high. Distance from 50d / 200d: 52.8% / 143.9%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
FBRX is held by 2 ETFs as of May 2026. Top owner: SBIO at 0.15% weight, $246K notional.
Held by 7 ETFs · $15M across latest filings · largest weight 0.86% (ATFV).
Top 2 by value, from SEC N-PORT-P filings dated May 2026.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | FBRX Jan avg: -12.11% median: -12.88% win: 25% σ: 18.55% n: 4 2022-04-12 → 2026-07-31 | FBRX Feb avg: -6.39% median: 2.62% win: 75% σ: 24.62% n: 4 2022-04-12 → 2026-07-31 | FBRX Mar avg: -7.01% median: -7.64% win: 25% σ: 8.75% n: 4 2022-04-12 → 2026-07-31 | FBRX Apr avg: -1.08% median: 2.93% win: 60% σ: 9.15% n: 5 2022-04-12 → 2026-07-31 | FBRX May avg: -4.36% median: -4.67% win: 40% σ: 20.14% n: 5 2022-04-12 → 2026-07-31 | FBRX Jun avg: 10.89% median: 1.96% win: 60% σ: 24.25% n: 5 2022-04-12 → 2026-07-31 | FBRX Jul avg: 46.53% median: -2.89% win: 40% σ: 119.98% n: 5 2022-04-12 → 2026-07-31 | FBRX Aug avg: -11.33% median: -6.49% win: 50% σ: 24.11% n: 4 2022-04-12 → 2026-07-31 (current) | FBRX Sep avg: -7.70% median: -18.97% win: 25% σ: 29.79% n: 4 2022-04-12 → 2026-07-31 | FBRX Oct avg: -14.76% median: -17.06% win: 25% σ: 11.57% n: 4 2022-04-12 → 2026-07-31 | FBRX Nov avg: 104.99% median: 19.98% win: 50% σ: 190.01% n: 4 2022-04-12 → 2026-07-31 | FBRX Dec avg: 31.35% median: 25.77% win: 100% σ: 34.99% n: 4 2022-04-12 → 2026-07-31 |